46.18EUR+6.01%Mkt Cap: 2.13B EURP/E: —Last update: 2026-05-14
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-121.72
PEG—
P/B-25.10
P/S65.20
EV/EBITDA-206.21
EV/Revenue66.36
EPS (TTM)-0.50
EPS (Forward)-0.36
Cash Flow & Leverage
FCF Yield-0.37%
FCF Margin-24.22%
Operating CF-33.42M EUR
CapEx (TTM)546.00K EUR
Net Debt/EBITDA-4.06
Net Debt42.57M EUR
Technical
SMA 5029.45 (+56.8%)
SMA 20019.68 (+134.6%)
Beta0.58
S&P 52W Chg24.23%
Avg Vol (30d)235.61K
Avg Vol (10d)434.10K
Technical Indicators
RSI (14)80.0
MACD4.1521
MACD Signal2.4498
MACD Hist.+1.7023
BB Upper44.81 EUR
BB Middle32.15 EUR
BB Lower19.49 EUR
BB Width78.75%
ATR (14)3.188 EUR
Vol Ratio (20d)1.05x
52W Range
3.27599% of range46.74
52W High46.74 EUR
52W Low3.275 EUR
Profitability
Gross Margin100.00%
EBITDA Margin-32.18%
Profit Margin-80.83%
Oper. Margin-196.42%
ROE28.36%
ROA-35.36%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity-1.13
Current Ratio1.09
Quick Ratio1.05
Book Value/Sh-1.7460 EUR
Cash/Share1.090 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.48.50M
Float31.07M
Insiders16.26%
Institutions37.55%
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)32.90 EUR
Target Range21.50 EUR – 45.00 EUR
# Analysts5
Company
Market Cap2.13B EUR
Enterprise Value2.16B EUR
Revenue (TTM)32.59M EUR
Gross Profit32.59M EUR
Net Income (TTM)-23.96M EUR
Revenue/Share0.6820 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees100
Last Price46.18 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISIN—